Comments
Ranbaxy Laboratories, on Monday, announced the launch of Infimab, the first Remicade (Infliximab) biosimilar in India.
The drug is used in treatment of inflammatory diseases, including rheumatoid arthritis, Crohn’s Disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and also psoriasis.
A company statement said, “Infimab is being introduced in the Indian market through a licensing partnership with Epirus Biopharmaceuticals, a US and Swiss-based biopharmaceutical company focused on the global development and commercialisation of biosimilar monoclonal antibodies.”
In a statement, Rajeev Sibal, Vice-President and Country Head-India Region, Ranbaxy, said that the drug will be available in India at a price point that is significantly discounted compared to the innovator drug Remicade.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.